Valuation Update With 7 Day Price Move • Jun 04
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to CN¥14.70, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 22x in the Medical Equipment industry in China. Total loss to shareholders of 36% over the past three years. Announcement • Jun 02
SWS Medical Unveils Next-Generation Blood Purification Solutions At ERA Congress 2026 SWS Medical will make its debut at the ERA Congress 2026 from June 3-6 in Glasgow, welcoming nephrologists, industry leaders, and partners at Booth D-350 to showcase its next-generation blood purification solutions. At ERA 2026, the company will showcase next-generation of dialysis and CRRT platforms designed to support intelligent automation, connected care, workflow efficiency, and integrated therapy delivery. Featured technologies include the SWS-4000 and SWS-6000 series, among China's leading dialysis platforms, which together accounted for an estimated 20% share of the country's dialysis machine market in 2025. The flagship SWS-6000 is the only dialysis machine in China with certified monitoring of key treatment parameters, while the SWS-4000 features an Online HDF system for sterile fluid production. Together, the platforms are designed to support safer, more efficient treatment through intelligent monitoring and automation. The CE-certified SWS-5000, China's No. 1 CRRT machine for three consecutive years, is an award-winning all-in-one platform designed to support integrated multi-organ blood purification therapies across renal, hepatic, cardiac, pulmonary, and pancreatic applications. The portfolio also includes advanced dialyzers manufactured using proprietary pre-vacuum pressure steam sterilization and 100% BPA-free materials to deliver high solute clearance and reliable ultrafiltration performance, alongside dialysis fluid filters and hemoperfusion cartridges for expanded blood purification therapies. Supporting the company's connected-care strategy, the Integrated Management Platform links dialysis centers, clinicians, and patients through the Data Hub, Patient Card, and Hemodialysis Management System, helping transform data into safer, smarter, care delivery. Reported Earnings • Apr 30
Full year 2025 earnings released: EPS: CN¥0.46 (vs CN¥0.22 in FY 2024) Full year 2025 results: EPS: CN¥0.46 (up from CN¥0.22 in FY 2024). Revenue: CN¥806.9m (up 42% from FY 2024). Net income: CN¥145.9m (up 106% from FY 2024). Profit margin: 18% (up from 13% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 15% per year. 
